| Company Name: |
Twochem Co.Ltd |
| Tel: |
021-021-58111628 15800915896 |
| Email: |
sales@twochem.com |
TAK-659 manufacturers
- TAK-659
-
- $3100.00
-
2026-05-11
- CAS:1312691-33-0
- Purity:
- Supply Ability: 10g
|
| | TAK-659 Basic information |
| Product Name: | TAK-659 | | Synonyms: | TAK-659;6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;Tak-659 free base;Mivavotinib;MIVAVOTINIB;TAK 659;TAK659;3H-Pyrrolo[3,4-c]pyridin-3-one, 6-[[(1R,2S)-2-aminocyclohexyl]amino]-7-fluoro-1,2-dihydro-4-(1-methyl-1H-pyrazol-4-yl)-;TAK-659 free base(Mivavotinib);TAK-659-01 | | CAS: | 1312691-33-0 | | MF: | C17H21FN6O | | MW: | 344.39 | | EINECS: | 604-604-1 | | Product Categories: | | | Mol File: | 1312691-33-0.mol |  |
| | TAK-659 Chemical Properties |
| Boiling point | 661.7±55.0 °C(Predicted) | | density | 1.58±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | pka | 10.90±0.20(Predicted) |
| | TAK-659 Usage And Synthesis |
| Uses | Mivavotinib is employed in the discovery of Lanraplenib, a tyrosine kinase inhibitor for autoimmune diseases. | | in vivo | TAK-659 (100 mg/kg/day; p.o.; for 10 days) treatment totally abrogates splenomegaly and tumor development in LMP2A/MYC mice in both pretumor and tumor cell transfer experiments[4].
TAK-659 treatment kills tumor cells, but not host cells within the spleen and tumors[4].
TAK-659 treatment abrogates metastasis of tumor cells into bone marrow[4].
| Animal Model: | LMP2A/MYC double transgenic mice[4] | | Dosage: | 100 mg/kg/day | | Administration: | Oral gavage; for 10 days | | Result: | Inhibited LMP2A-induced tumor cell survival in vivo. |
|
| | TAK-659 Preparation Products And Raw materials |
|